Fulvestrant

Fulvestrant is a selective estrogen receptor degrader (SERD) used in the treatment of hormone receptor-positive metastatic breast cancer. It works by binding to estrogen receptors, blocking estrogen signaling, and promoting receptor degradation, thereby inhibiting tumor growth. Fulvestrant was first developed in the 1990s as a more effective alternative to existing anti-estrogen therapies like tamoxifen. Its development aimed to overcome resistance seen with earlier endocrine treatments. The drug received approval from the FDA in 2002 for use in postmenopausal women with advanced breast cancer. Fulvestrant is administered via intramuscular injection due to its poor oral bioavailability. Clinical trials demonstrated its efficacy both as a single agent and in combination with other targeted therapies. Over time, it has become an important option in managing hormone-driven breast cancers. The drug represents a shift toward more targeted endocrine therapies in oncology. Fulvestrant’s introduction marked a significant advancement in personalized cancer treatment strategies.